Il carcinoma esofageo radioindotto: prognosi e trattamento
Rita Alfieri(Istituto Oncologico Veneto), Ermanno Ancona(University of Padua), Alberto Ruol(University of Padua), Silvia Michieletto(Istituto Oncologico Veneto), Gianpietro Zanchettin(University of Padua), Carlo Castoro(Humanitas University), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Chiara Tosolini(University of Padua), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Caterina Boso, Matteo Cagol(Istituto Oncologico Veneto)
CNR Solar (Scientific Open-access Literature Archive and Repository) (Consiglio Nazionale delle Ricerche)
January 1, 2009
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k